CD4+ Regulatory T Cells in Human Cancer: Subsets, Origin, and Molecular Regulation.
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
02 Apr 2024
02 Apr 2024
Historique:
received:
11
07
2023
revised:
18
09
2023
accepted:
20
12
2023
medline:
2
4
2024
pubmed:
2
4
2024
entrez:
2
4
2024
Statut:
ppublish
Résumé
CD4+CD25hiFOXP3+ regulatory T cells (Treg) play major roles in the maintenance of immune tolerance, prevention of inflammation, and tissue homeostasis and repair. In contrast with these beneficial roles, Tregs are abundant in virtually all tumors and have been mechanistically linked to disease progression, metastases development, and therapy resistance. Tregs are thus recognized as a major target for cancer immunotherapy. Compared with other sites in the body, tumors harbor hyperactivated Treg subsets whose molecular characteristics are only beginning to be elucidated. Here, we describe current knowledge of intratumoral Tregs and discuss their potential cellular and tissue origin. Furthermore, we describe currently recognized molecular regulators that drive differentiation and maintenance of Tregs in cancer, with a special focus on those signals regulating their chronic immune activation, with relevant implications for cancer progression and therapy.
Identifiants
pubmed: 38562083
pii: 741943
doi: 10.1158/2326-6066.CIR-23-0517
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-399Subventions
Organisme : Ministero della Salute (Italy Ministry of Health)
ID : GR-2018-12367258
Organisme : European Molecular Biology Organization (EMBO)
ID : ALTF 663-2022
Organisme : Fondazione AIRC per la ricerca sul cancro ETS (AIRC)
ID : MFAG 26471
Organisme : Cancer Research Institute (CRI)
ID : 3914
Informations de copyright
©2024 American Association for Cancer Research.